SCHEMBL4276913

SCHEMBL4276913

CCOc1cc(C(N)=O)ccc1OCc1ccccc1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.65
MAPK1 P28482 1/20 0.65
HSD17B10 Q99714 1/20 0.62
POLB P06746 2/20 0.60
NPC1 O15118 1/20 0.60
HPGD P15428 1/20 0.60
RAB9A P51151 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
MAPT P10636 1/20 0.60
THRB P10828 1/20 0.60
LMNA P02545 2/20 0.60
MRGPRX4 Q96LA9 1/20 0.59
SMPD1 P17405 1/20 0.59
HDAC1 Q13547 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
ALDH1A1 P00352 1/20 0.58
F2 P00734 1/20 0.57
F10 P00742 1/20 0.57
PRSS1 P07477 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4278858 0.93 PARP10 (0.64) KDM4EMAPK1HSD17B10NPC1HPGD
SCHEMBL34465358 0.93 PARP10 (0.64) KDM4EMAPK1HSD17B10NPC1HPGD
SCHEMBL4270566 0.89 SMPD1 (0.73) KDM4EMAPK1NPC1HPGDRAB9A
SCHEMBL4280782 0.89 MRGPRX4 (0.74) KDM4EHSD17B10POLBNPC1HPGD
SCHEMBL4278415 0.87 NPC1 (0.73) KDM4EMAPK1NPC1HPGDRAB9A
SCHEMBL1402177 0.87 MAPK1 (0.84) MAPK1HSD17B10POLBNPC1RAB9A
SCHEMBL17037223 0.85 SMPD1 (0.55) KDM4EMAPK1HSD17B10NPC1HPGD
SCHEMBL30820546 0.85 SMN1; SMN2 (0.62) KDM4EHSD17B10POLBNPC1HPGD
SCHEMBL18660058 0.85 SMN1; SMN2 (0.62) KDM4EHSD17B10POLBNPC1HPGD
SCHEMBL4279981 0.85 HSD17B10 (0.61) KDM4EHSD17B10POLBNPC1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICALC., LTD. (JP) 2026-04-23 US disclosed
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-05-09 US disclosed
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2022-08-25 US disclosed
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2020-03-12 US disclosed
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-03-07 US disclosed
US-RE46792-E1 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2018-04-17 US disclosed
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-08-03 US disclosed
EP-1954684-B1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2014-05-07 EP disclosed
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-04-10 US disclosed
US-8637559-B2 Oxazole compound and pharmaceutical composition OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-01-28 US disclosed
CN-101309912-B Oxazole compound and pharmaceutical composition OTSUKA PHARMA CO LTD 2013-09-25 CN disclosed
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-09-03 US disclosed
CN-101309912-A Oxazole compound and pharmaceutical composition OTSUKA PHARMA CO LTD (JP) 2008-11-19 CN disclosed
EP-1954684-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION Otsuka Pharmaceutical Co., Ltd. (JP) 2008-08-13 EP disclosed
WO-2007058338-A9 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMA CO LTD (JP) 2007-11-01 WO disclosed
WO-2007058338-A2 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216260-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A KDM4E 1260/4885MAPK1 453/4885HSD17B10 552/4885
US-20140100226-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A KDM4E 1260/4885MAPK1 453/4885HSD17B10 552/4885
US-20240148699-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A KDM4E 1260/4885MAPK1 453/4885HSD17B10 552/4885
US-20260108497-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE7B, PDE4B, PDE1B KDM4E 907/4885MAPK1 1461/4885HSD17B10 910/4885
US-20090221586-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A KDM4E 1260/4885MAPK1 453/4885HSD17B10 552/4885
US-20200078340-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A KDM4E 1260/4885MAPK1 453/4885HSD17B10 552/4885
US-20220265613-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A KDM4E 1383/4885MAPK1 369/4885HSD17B10 469/4885
US-20190070151-A1 OXAZOLE COMPOUND AND PHARMACEUTICAL COMPOSITION PDE3B, PDE4A, PDE3A KDM4E 1260/4885MAPK1 453/4885HSD17B10 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.